364 related articles for article (PubMed ID: 15250019)
1. Empirical antifungal therapy in treating febrile neutropenic patients.
Wingard JR
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
[TBL] [Abstract][Full Text] [Related]
2. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
Sobel JD
Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
[TBL] [Abstract][Full Text] [Related]
3. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
4. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
Martino R; Viscoli C
Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
[TBL] [Abstract][Full Text] [Related]
5. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
7. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
8. Febrile neutropenia in haematological malignancies.
Sharma A; Lokeshwar N
J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
[TBL] [Abstract][Full Text] [Related]
9. Empiric antifungal therapy in patients with febrile neutropenia.
Ferrara JJ; MacDougall C; Gallagher JC
Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
Metcalf SC; Dockrell DH
J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
[TBL] [Abstract][Full Text] [Related]
11. Empirical antifungal therapy.
Klastersky J
Int J Antimicrob Agents; 2004 Feb; 23(2):105-12. PubMed ID: 15013034
[TBL] [Abstract][Full Text] [Related]
12. Fungal infections in neutropenic cancer patients.
Parvez T
J Coll Physicians Surg Pak; 2003 Nov; 13(11):669-73. PubMed ID: 14700501
[TBL] [Abstract][Full Text] [Related]
13. Candida infections in non-neutropenic children after the neonatal period.
Hacimustafaoglu M; Celebi S
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):923-40. PubMed ID: 21973304
[TBL] [Abstract][Full Text] [Related]
14. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
Sugar AM
Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial prophylaxis in febrile neutropenia.
Yoshida M; Ohno R
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S65-7. PubMed ID: 15250025
[TBL] [Abstract][Full Text] [Related]
16. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
Imhof A; Walter RB; Schaffner A
Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
[TBL] [Abstract][Full Text] [Related]
18. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
20. [Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients].
Zielińska E
Przegl Epidemiol; 2003; 57(2):299-307. PubMed ID: 12910598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]